In this part 2 of a 2-part interview regarding the presentation “Beyond Traditional Markets: The Strategic Importance of Emerging Pharma Trends and CDMO Innovation” at CPHI Europe 2025, held Oct 28-30 in Frankfurt, Germany, panelist J.D. Mowery, president, Bora Pharmaceuticals, provides insight into pivotal operational challenges and necessary evolutions within the biopharmaceutical industry. The discussion centered on the necessity of establishing global standards for sustainability, the operational hurdles of artificial intelligence (AI) implementation, and the need to increase trust in outsourcing partnerships.
Mowery asserts that…